International Journal of Pediatrics

Advances in Iron Chelation Therapy: Towards A New Oral Formulation

Farid Ghazizadeh; Mehran Noroozi; Lachin Seifi

Volume 10, Issue 7 , July 2022, , Pages 16387-16395

https://doi.org/10.22038/ijp.2022.65351.4929

Abstract

Background: Patients with thalassemia major require regular monthly blood transfusion and excess iron from multiple blood transfusion deposits in different organs of the body, causing ... Read More Background: Patients with thalassemia major require regular monthly blood transfusion and excess iron from multiple blood transfusion deposits in different organs of the body, causing different organ damages. Cardiac iron overload is the main cause of death in patients with thalassemia major.Method: The aim of this study was to determine the effectiveness of Deferasirox (Nanojade) produced in Iran for the first time as a medicine in reducing iron overload of chronic blood transfusion in patients with Beta-thalassemia major. This is a pre-post quasi-experimental study that was performed on patients with thalassemia major involved in lifelong regular monthly blood transfusions. In this study, based on the existing protocols, injectable and dissolving iron chelating regimes were changed to a new generation of deferasirox oral tablets. To determine the effect of Nanojade, the mean level of the last three serum ferritin levels, before changing chelation, was compared with the serum ferritin levels after starting Nanojade. In the course of treatment, the possible side effects of Nanojade in various organs were monitored regularly.Results: The mean age of the patients was 16 years (ranging between 3 and 39 years). None of the patients had renal failure, elevated creatinine, or proteinuria with Nanojade. The most important side effect was elevated liver enzyme levels. The mean starting dose of Nanojade was 19.86± 5.78 mg/kg and the mean of the last dose was 23.41 ± 5.49 mg/kg. There was a statistically significant difference between the amount of ferritin at baseline with the serum ferritin of 6 and 18 months after chelation with Nanojade (P = 0.001).Conclusion: chelation with Nano Jade had less renal and hepatic side effects; and all of the patients had good compliance and significant reduction in the serum ferritin level in comparison to the results of other studies regarding the similar foreign deferasirox products.

Regular Reminding of the Potential Serious Complications of Poor Adherence to Treatment: A Strategy for Improving Treatment Adherence in Beta-Thalassemia Major Patients

Amir Emami Zeydi; Abbas Heydari; Hossein Karimi Moonaghi

Volume 5, Issue 12 , December 2017, , Pages 6201-6202

https://doi.org/10.22038/ijp.2017.25718.2190

Abstract

Globally, β-Thalassemia Major (β-TM) is the most commonly inherited hemolytic anemia, with a high incidence rate in Southeast Asia, the Middle East and Mediterranean countries. ... Read More

Effect of Combined versus Monotherapy with Deferoxamine and Deferiprone in Iron Overloaded Thalassemia Patients: a Randomized Clinical Trial

Sasan Hejazi; Omid Safari; Reza Arjmand; Mostafa Qorbani; Kumars Pourrostami; Abdolmohammad Safari; Arezo Hemmati

Volume 4, Issue 6 , June 2016, , Pages 1959-1965

https://doi.org/10.22038/ijp.2016.6871

Abstract

Background: Patients with transfusional iron overload have depended on iron chelation therapy and improving chelation regimens have been of the highest priority. The aim of this study ... Read More

Correlation between Heart and Liver Iron Levels Measured by MRI T2* and Serum Ferritin in Patients with β-thalassemia Major

Razieh Taghizadeh Sarvestani; Borhan Moradveisi; Farzad Kompany; Ebrahim Ghaderi

Volume 4, Issue 3 , March 2016, , Pages 1559-1567

https://doi.org/10.22038/ijp.2016.6587

Abstract

Background Transfusion-induced iron overload leads to many complications in patients with β-thalassemia major. This study aimed to compare the level of iron stored in the liver ... Read More

International Journal of Pediatrics

Articles in Press

Current Issue

Volume 12 (2024)

Volume 11 (2023)

Volume 10 (2022)

Volume 9 (2021)

Volume 8 (2020)

Volume 7 (2019)

Volume 6 (2018)

Volume 5 (2017)

Volume 4 (2016)

Volume 3 (2015)

Volume 2 (2014)

Volume 1 (2013)

Keywords = Iron overload

Advances in Iron Chelation Therapy: Towards A New Oral Formulation

Abstract

Regular Reminding of the Potential Serious Complications of Poor Adherence to Treatment: A Strategy for Improving Treatment Adherence in Beta-Thalassemia Major Patients

Abstract

Effect of Combined versus Monotherapy with Deferoxamine and Deferiprone in Iron Overloaded Thalassemia Patients: a Randomized Clinical Trial

Abstract

Correlation between Heart and Liver Iron Levels Measured by MRI T2* and Serum Ferritin in Patients with β-thalassemia Major

Abstract